Taxol in the management of cancers of the breast and the ovary

Cancer Investigation

Volumn 18, Issue 3, 2000, Pages 242-260

  Khayat, David ^a   Antoine, Eric Charles ^a   Coeffic, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; NAVELBINE; PACLITAXEL; TRASTUZUMAB;

ARTICLE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; DOSE CALCULATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG RESEARCH; HUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0034105412     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357900009031828     Document Type: Article

References (123)

1. Harris JR, Morrow M, Bonadonna G: Cancer of the breast. In: Cancer: Principles and Practice of Oncology, 4th ed., edited by JR DeVita, S Hellman, SA Rosenberg, Philadelphia, Lippincott, 1993, pp 1264-1272.
2. Holmes F, Walters RS, Theriault RL, et al: Phase II trial of Taxol, and active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797, 1991 (abstract).
3. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11: 1943, 1993 (abstract).
4. Vermorken JB, Huizing MT, Liefting AJM, et al: High-dose Taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy. Eur J Cancer 29A:83, 1993 (abstract).
5. Nabholtz JM, Gelmon K, Botenbal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer. Proc Am Soc Clin Oncol 12:60, 1993 (abstract).
6. Seidman A. Paclitaxel: the long and short of it. Cancer J Sci Am 1:250-251, 1995.
7. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995.
8. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996.
9. Winner E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342. Am Soc Clin Oncol 17:101a, 1998 (abstract).
10. Peretz T, Sulkes A, Chollet P, et al: A multicenter, randomized study of two schedules of paclitaxel (PTX) in patients with advanced breast cancer (ABC). Eur J Cancer 31A(Suppl 5):S75, 1995 (abstract).
11. Mamounas E, Brown A, Smith R, et al: Effect of taxol duration of infusion in advanced breast cancer (ABC) results from NSABP B-26 trial comparing 3-to 24-hr infusion of high-dose taxol. Am Soc Clin Oncol 17:101a, 1998 (abstract).
12. Holmes FA, Valero V, Buzdar AU, et al: Final results: randomized phase III trial of paclitaxel by 3-hr versus 96-hr infusion in patients (pt) with met breast cancer (MBC). Am Soc Clin Oncol 17:110a, 1998 (abstract).
13. Lopes NM, Adams EF, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:234-242, 1993.
14. Liebmann JE, Cook JA, Lipschultz C, et al: Cytotoxic studies of paclitaxel in human tumor cell lines. Br J Cancer 68:1104-1109, 1993.
15. Wu-Wong J, Chiou W, Han E, et al: Effects of paclitaxel on cell proliferation, apoptosis and angiogenesis. Proc Am Assoc Cancer Res 38:531, 1997 (abstract).
16. Torres KE, Castillo G, Horwitz SB: Induction of apoptosis by low concentrations of Taxol is not dependent on a G2/M block. Proc Am Assoc Cancer Res 38:530, 1997 (abstract).
17. Seidman AD: One-hour paclitaxel via weekly infusion: dose-density with enhanced therapeutic index. 12(Suppl 1): 19-22, 1998.
18. Chang AY, Boros L, Asbury R, et al: Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer. Semin Oncol 24(Suppl 17): S17-44-S17-47, 1997.
19. Lau DH, Young L, Xue L, et al: Paclitaxel: an ongoing antagonist in a metastatic breast cancer model. Am Soc Clin Oncol 17: 107a, 1998 (abstract).
20. Seidman AD, Murphy B, Hudis C, et al: Activity of Taxol® (T) by weekly 1 hour infusion in patients (pts) with metastatic breast cancer (MBC): a phase II and pharmacologic study. Am Soc Clin Oncol 16:148a, 1997 (abstract).
21. Sikov W, Akerley W, Strenger R, et al: Weekly high-dose paclitaxel (P) demonstrates significant activity in advanced breast cancer (BC). Am Soc Clin Oncol 17:112a, 1998 (abstract).
22. Henderson IC: Chemotherapy for metastatic disease. In: Breast Disease, 2nd ed., edited by JR Harris, S Hellman, JC Henderson, et al, Philadelphia, Lippincott, 1991, pp 604-665.
23. Reichman B, Seidman A, Crown J, et al: Paclitaxel and recombinant human granulocyte colony stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
24. Wilson W, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer. A phase I/ II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994.
25. Sledge GW, Neuberg D, Ingle J, et al: Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin + paclitaxel (A + T) as first-line therapy for metastatic breast cancer (MBC): an intergroup trial. Am Soc Clin Oncol 16:1a, 1997 (abstract).
26. Gamucci T, Piccart M, Brüning P, et al: Single agent taxol (T) versus doxorubicin (D) as first-line chemotherapy (CT) in advanced breast cancer (ABC). Final results of an EORTC randomized study with crossover. Am Soc Clin Oncol 17:111a, 1998 (abstract).
27. Fischerman JS, McCahe M, Noone M, et al: Phase I study of Taxol, doxorubicin plus granulocyte colony-stimulating factor in patients with metastatic breast cancer. Monogr Natl Cancer Inst 15:189-194, 1993.
28. Sledge GW, Robert N, Sparano JA, et al: Paclitaxel (Taxol)/ doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994.
29. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
30. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687-693, 1996.
31. Gianni L, Capri G, Tarenzi E, et al: Efficacy and cardiac effects of 3-hour paclitaxel plus bolus doxorubicin in women with untreated metastatic breast carcinoma. Proc Am Soc Clin Oncol 15:116, 1996 (abstract).
32. Schwartsmann G, Menke CH, Caleffi M, et al: Phase II trial of Taxol, doxorubicin plus G-CSF in patients with metastatic breast cancer. Am Soc Clin Oncol 15:126, 1996 (abstract).
33. Gianni L, Dombernowsky P, Sledge G, et al: Cardiac function following combination therapy with taxol® (T) and doxorubicin α for advanced breast cancer (ABC). Am Soc Clin Oncol 17: 115a, 1998 (abstract).
34. Praga C, Trave F, Petroccione A: Anthracycline-induced cardiotoxicity and its relevance in cancer treatment. In: Clinical Measurements in Drug Evaluation, edited by WS Nimmo, GT Tucker, London, UK, Wolfe Publishing, 1991, pp 131-142.
35. Dombernowsky P, Boegaard M, Andersen E, et al: Doxorubicin plus paclitaxel in advanced breast cancer. Semin Oncol 24(Suppl 17):S17-15-S17-18, 1997.
36. Frassineti GL, Zoli W, Silvestro L, et al: Paclitaxel plus doxorubicin in breast cancer: an Italian experience. Semin Oncol 24(Suppl 17):S17-19-S17-25, 1997.
37. Lück HJ, Thomssen C, du Bois A, et al: Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer. Semin Oncol 24(Suppl 17):S17-35-S17-39, 1997.
38. Carmichael J, Jones A, Hutchison T: A phase II trial of epirubicin plus paclitaxel in metastatic breast cancer. Semin Oncol 24(Suppl 17):S17-44-S17-47, 1997.
39. Conte PF, Gennari A, Salvadori B, et al: Paclitaxel plus epirubicin in advanced breast cancer. Oncology 12(Suppl 1):40-44, 1998.
40. Tolcher AW: Paclitaxel couplets with cyclophosphamide or cisplatin in metastatic breast cancer. Semin Oncol 23(Suppl 1):37, 1996 (abstract).
41. Kennedy MJ, Armstrong D, Donehower R, et al: The hematologic toxicity of the Taxol/Cytoxan doublet is sequence-dependent. Proc Am Soc Clin Oncol 13:74, 1994 (abstract).
42. Sessa C, Pagani O, Parma G, et al: Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer. Semin Oncol 22(Suppl 6):112, 1995 (abstract).
43. Fields KK, Partyka JS, Perkins JB, et al: Cyclophosphamide and Taxol® is an active salvage regimen in patients with anthracycline refractory metastatic breast cancer. Proc Am Soc Clin Oncol 16:168a, 1997 (abstract).
44. Hortobagyi GN, Ibrahim N: Paclitaxel-containing combination chemotherapy for metastatic breast cancer. Semin Oncol 23(Suppl 1):53, 1996 (abstract).
45. Weiselberg L, Budman DR, O'Mara V, et al: Phase I trial of sequential vinorelbine-paclitaxel in patients with metastatic breast cancer: early evidence of tolerability and efficacy. Proc Am Soc Clin Oncol 15:A54, 1996 (abstract).
46. Michelotti A, Gennari A, Salvadori B, et al: Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients. Semin Oncol 23(Suppl 1):38, 1996 (abstract).
47. Vici P, Amodio A, Di Lauro L, et al: Simultaneous infusion of vinorelbine (VNB) and paclitaxel (P) as first-line chemotherapy (CT) in advanced breast cancer (ABC) patients (patients). Proc Am Soc Clin Oncol 16:196a, 1997 (abstract).
48. Chang AY, Garrow GC: Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast cancer and lung cancer. Semin Oncol 22(Suppl 5):66, 1995 (abstract).
49. Jaremtchuk A, Matwiejuk M, Polera O, et al: Feasibility study of the combination of Navelbine® and paclitaxel (PCL) in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 16:175a, 1997 (abstract).
50. Romero Acuña L, Langhi M, Pérez J, et al: Vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy (FLC) in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 16:188a, 1997 (abstract).
51. Martin M, Casado A, Segura PP, et al: Paclitaxel plus vinorelbine in metastatic breast cancer patients with contraindications to receive anthracyclines. Oncology 12(Suppl 1):28-30, 1998.
52. Paul DM, Garett AM, Meshad M, et al: Paclitaxel and 5Fluorouracil in metastatic breast cancer: The US experience. Semin Oncol 23(Suppl 1):48, 1996 (abstract).
53. Zaniboni A, Guarinoni L, Distefano L, et al: Taxol, folinic acid and fluoruouracil (TAFF) as second-line treatment for advanced breast cancer (ABC) (Meeting abstract). Proc Am Soc Clin Oncol 15:A202, 1996 (abstract).
54. Fornasreio A, Ghiotto C, Daniele O, et al: Paclitaxel (Tax) + Fluorouracil (Fu): phase I/II study in metastatic breast cancer (MBC). Breast Cancer Res Treat 37(Suppl):302, 1996 (abstract).
55. Elkordy M, Matters L, Coniglio D, et al: The effect of continuous infusion 5-FU (CI-F) with or without taxol (T) as induction therapy in stade IV breast carcinoma (BC) (Meeting abstract). Proc Am Soc Clin Oncol 13:A184, 1994 (abstract).
56. Madajewicz S, LiPera W, Pendyala L, et al: Phase I study of 96 hr continuous intravenous infusion (CI) of taxol (T) followed by 24 hr CI of 5-fluorouracil (5-FU) and folinic acid (FA) (Meeting abstract). Proc Am Soc Clin Oncol 14:A1589, 1995.
57. Gleissner A, Hellmann A, Koldehoff M, et al: Phase I study of paclitaxel and 5-fluorouracil as second-line therapy in patients with metastatic breast cancer. Breast Cancer Res Treat 37(Suppl):312, 1996 (abstract).
58. Takimoto CH, Morrison GB, Frame JN, et al: A phase I and pharmacologic trial of paclitaxel (Taxol®) and 5-fluorouracil (5-FU) plus leucovorin (LCV) in patients with solid tumors. Proc Am Soc Clin Oncol 14:471, 1995 (abstract).
59. Klaassen U, Harstrick A, Wilke H, et al: Preclinical and clinical study results of the combination of paclitaxel and 5-fluorouracil/ folinic acid in the treatment of metastatic breast cancer. Semin Oncol 23(Suppl 1):44, 1996 (abstract).
60. Hainsworth JD, Jones SE, Erland JB, et al: Paclitaxel, mitoxantrone, 5-fluorouracil, and high dose leucovorin (P-NFL) in the the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 14:A64, 1995 (abstract).
61. Klaassen U, Wilke H, Miller CH, et al: Weekly high-dose 24-hour infusional 5-FU plus leucovorin (HD5-FD/LV) in combination with paclitaxel (P) and cisplatin (C) in the first-line treatment of metastatic breast cancer (MBC): results of a phase II study. Proc Am Soc Clin Oncol 16:177a, 1997 (abstract).
62. Sledge GW, Loehrer PJ, Roth BJ, et al: Cisplatin as first-line therapy therapy for metastatic breast cancer. J Clin Oncol 6: 1811-1814, 1988.
63. Smith IE, Talbot DC: Cisplatin and its analogues in the treatment of advanced breast cancer. A review. Br J Cancer 65:787-793, 1992.
64. Berry J, Ezzat A, El-Warith A, et al: Sequential taxol/platinum: pilot study in metastatic breast cancer. Proc Am Soc Clin Oncol 14:136, 1995 (abstract).
65. Ezzat A, Rahal M, Baearbashi S, et al: Pathological response (CpR) induced by circadian Taxol® (T) and cis-platinum (P) in locally advanced breast cancer (ABC). Proc Am Soc Clin Oncol 16:168a, 1997 (abstract).
66. Gelmont KA, O'Reilly SE, Tolcher AW, et al: Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 14:1185, 1996 (abstract).
67. McCaskill-Stevens WJ, Fox S, Harlan J, et al: Phase I/II study of biweekly paclitaxel (P) and carboplatin (C) in the treatment of patients (patients) with stage IV breast carcinoma. Proc Am Soc Clin Oncol 183a, 1997 (abstract).
68. A Hellenic Cooperative Oncology Group Study, Aravantinos G, Athanassiades A, et al: Combination of carboplatin and paclitaxel in anthracyline-resistant advanced breast cancer (ABC). A Hellenic Cooperative Oncology Group Study. Proc Am Soc Clin Oncol 16:168a, 1997 (abstract).
69. Demetri G, Berry D, Norton L, et al: Clinical outcomes of node positive breast cancer patients treated with dose-intensified adryamycin/cyclophosphamide followed by Taxol as adjuvant systemic chemotherapy in (CALGB9141). Proc Am Soc Clin Oncol 16:143a, 1997 (abstract).
70. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin α dose level in the adjuvant chemotherapy of patients (patients) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstract).
71. Hudis CA: Dose-dense paclitaxel-containing adjuvant therapy for breast cancer. Oncology 12(Suppl 1):16-18, 1998.
72. Anelli A, Albuquerque AD, Tabacof J, et al: Paclitaxel and doxorubicin as neoadjuvant chemotherapy in locally advanced breast cancer-preliminary results. Proc Am Soc Clin Oncol 16:158a, 1997 (abstract).
73. Schwartzberg LS, Birch R, Weaver CH, et al: High pathological complete response (CR) rate to sequential doxorubicin and paclitaxel primary chemotherapy for locally advanced breast cancer (LABC). Am Soc Clin Oncol 17:112a, 1998 (abstract).
74. Slamon D, Leyland-Jones B, Shak S, et al: Addition of Herceptin™ (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer multinational controlled phase III trial. Am Soc Clin Oncol 17:98a, 1998 (abstract).
75. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47:2486-2493, 1987.
76. Donehower RC, Rowinsky EK, Grochow LB, et al: Phase I trial of taxol in patients with advanced cancer author. Cancer Treat Rep 71:1171-1177, 1987.
77. Einzig AI, Wiernik PH, Sasloff J, et al: Phase II study and long term follow-up of patients treated with Taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10:1748-1753, 1992.
78. McGuire WP, Rowinsky EK, Rosenheim NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced epithelial neoplasm. Ann Intern Med 11:273-279, 1989.
79. Thigpen T, Blessing J, Ball H, et al: Phase II trial of Taxol as second line therapy for ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 12:1748-1753, 1994.
80. Athanassiou A, Pectasides D, Vathalitis I, et al: Taxol patients with cisplatin or carboplatin refractory ovarian carcinoma. Proc Am Soc Clin Oncol 13:A870, 1994 (abstract).
81. Mendiola C, Garcia-Ribas I, Cubedo R, et al: High response rate of taxol in platinum pretreated advanced ovarian cancer. Proc Am Soc Clin Oncol 16:A1276, 1995 (abstract).
82. Aravantinos G, Skarlos DV, Kosmidis P, et al: A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group Study. Eur J Cancer 33:160-163, 1997.
83. Blom R, Palm N, Simonsen E: Paclitaxel (Taxol) monotherapy in the treatment of progressive and recurrent ovarian carcinoma after platinum-based chemotherapy. Acta Oncol 35:733-736, 1996.
84. Du Bois A, Lück HJ, Buser K, et al: Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with platinum. Eur J Cancer 33:379-384, 1997.
85. Nardi M, Aloe A, De Marco S, et al: Paclitaxel as salvage therapy in advanced pretreated ovarian cancer: a phase II study. Am J Clin Oncol 20:230-232, 1997.
86. Noda K, Ikeda M, Kudo R, et al: Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion. Gan To Kagaku Ryoho 23:317-325, 1996.
87. Phillips KA, Friedlander M, Olver I, et al: Australasian multicenter phase II study of paclitaxel (Taxol) in relapsed ovarian cancer. Aust N Z J Med 25:337-343, 1995.
88. Trimble EL, Adamas JD, Vena D, et al: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to national cancer institute treatment referral center 9103. J Clin Oncol 11:2405-2410, 1993.
89. Gore ME, Levy V, Rustin G, et al: Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience. Royal Marsden NHS Trust, London, UK. Br J Cancer 72:1016-1019, 1995.
90. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High dose versus low dose and long versus short infusion. J Clin Oncol 12: 2654-2666, 1994.
91. Fennelly D, Aghajanian C, Shapiro F, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997.
92. Löffler TM, Freund W, Lipke J, et al: Schedule and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. Semin Oncol 23:32-34, 1996.
93. 2 in pretreated patients with breast and ovarian cancer. Proc Am Soc Clin Oncol 16:A568, 1997 (abstract).
94. Raymond E, Hanauske A, Faivre S, et al: Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units. Anticancer Drugs 8:379-385, 1997.
95. Markman M, Rose PG, Jones E, et al: Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 16:1849-1851, 1998.
96. Soulie P, Trandafir L, Taamma A: Schedule-dependent paclitaxel tolerance/activity: data from a 7 day infusion phase I study with pharmacokinetics in paclitaxel refractory ovarian cancer. Anticancer Drugs 8:763-766, 1997.
97. Goldberg JM, Piver MS, Hempling RE, et al: Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer. Gynecol Oncol 63:312-317, 1996.
98. Johnston CM, Pearl ML, Reynolds RK, et al: Treatment of refractory ovarian carcinoma with paclitaxel and cisplatin after treatment failure with single-agent paclitaxel. Eur J Gynaecol Oncol 16:439-447, 1995.
99. Reed E, Kohn EC, Sarosy G, et al: Paclitaxel, cisplatin, cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 22:90-96, 1995.
100. Poole C, Perren TJ, Jordan SD et al: Sequential paclitaxel and cisplatin chemotherapy in patients with newly diagnosed epithelial ovarian cancer. Proc Am Soc Clin Oncol 16:A1271, 1997.
101. Bolis G: Pilot study with fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Semin Oncol 22:32-34, 1995.
102. Bolis G, Scarfone G, Villa A, et al: A phase I trial with fixed-dose carboplatin and escalating doses of paclitaxel in advanced ovarian cancer. Semin Oncol 24:25, 1997 (abstract).
103. Martoni A, Zamagni C, Gentile A, et al: A phase I study of paclitaxel and carboplatin as first line chemotherapy in stage III-IV ovarian cancer. Proc Am Soc Clin Oncol 16:A860, 1997 (abstract).
104. Meerpohl HG, du Bois A, Kühnle H, et al: Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer. Semin Oncol 22:7-12, 1995.
105. ten Bokkel Huinink W, Veenhof C, Heimerhorst T, et al: Paclitaxel plus carboplatin in the treatment of ovarian cancer. Semin Oncol 22:97-100, 1995.
106. Huizing MT, van Warmerdam LJ, Rosing H: A phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15:1953-1964, 1997.
107. du Bois A, Luck HJ, Bauknecht T, et al: Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 8:355-361, 1997.
108. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 4-6, 1996.
109. Muggia FM, Brady PS, Brady MF, et al: Phase III of cisplatin or paclitaxel versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study #132. Proc Am Soc Clin Oncol 16:A1257, 1997 (abstract).
110. Calvert AH, Boddy A, Bailey NP, et al: Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91-98, 1995.
111. Guastalla JP, Pujade-Lauraine E, Weber B, et al: Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma. A multicenter GINECO (Group d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 9:37-43, 1998.
112. Neijt JP, Hansen M, Hansen SW, et al: Randomized phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, HC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Annu Meet Am Soc Clin Oncol 16: A1259, 1997 (abstract).
113. Kohn EC, Sarosy GA, Davis P, et al: A pilot study of cyclophosphamide (CTX), paclitaxel (T), and cisplatin (P) with G-CSF for newly diagnosed ovarian cancer patients. Proc Am Soc Clin Oncol 15:A757, 1996 (abstract).
114. Coeffic D, Benhammouda A, Antoine EC, et al: Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma. Semin Oncol 24:S2-38-S2-40, 1997.
115. Young RC, Perez CA, Hoskins WJ: Cancer of the ovary. In: Cancer: Principles and Practice of Oncology, edited by VT De Vita, S Hellman, SA Rosenberg, Philadelphia, J.B Lippincott, 1993, 1226-1263.
116. Miglietta L, Amoroso D, Bruzzone M, et al: Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. Oncology 54:102-107, 1997.
117. Bunnell CA, Thompson L, Buswell L, et al: A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. Cancer 82:561-566, 1998.
118. Veldhuis GJ, Willemse PH, Beijnen JH, et al: Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study. Br J Cancer 75:703-709, 1997.
119. Naumann RW, Alvarez RD, Omura GD, et al: A phase I study of paclitaxel and cisplatin with escalating doses of doxorubicin in patients with previously untreated epithelial ovarian cancer. Proc Am Soc Clin Oncol 16:A1333, 1997 (abstract).
120. Romanini A, Tanganelli L, Galata M, et al: Epidoxorubicin, carboplatin and taxol in advanced epithelial ovarian cancer patients with residual disease more than 2 cm after surgery: a phase I study (Meeting abstract). Proc Annu Meet Am Assoc Cancer Res 38:A1504, 1997 (abstract).
121. Hill ME: G-CAT (GCSF, cis/carboplatin, adriamycin and Taxol) for advanced ovarian cancer: active but toxic. Proc Annu Meet Am Soc Clin Oncol 16:A1321, 1997.
122. O'Reilly S, Fleming GF, Barker SD, et al: Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol 15:177-186, 1997 .
123. Piccart MJ: Cisplatin/paclitaxel versus cisplatin/cyclophosphamide for advanced epithelial ovarian cancer: preliminary results from a large European-Canada intergroup trial. European Cancer Conference, Hamburg, 1987, pp 8-9.